Skip to main content
Photo header of senior man
Senior woman header
Senior woman header

DIAGNOSTIC INSIGHTS FOR LIFE®

CND’s Syn-One Test® offers physicians and patients an accurate, convenient, evidence-based tool to help diagnose a synucleinopathy. And our mission has just begun.

Learn More
Senior man header
Senior woman header
Senior woman header

DIAGNOSTIC INSIGHTS FOR LIFE

CND’s Syn-One Test® offers physicians and patients an accurate, convenient, evidence-based tool to help diagnose a synucleinopathy. And our mission has just begun.

Learn More

Syn-One Test named a top 2024 medical innovation by NIH. 50,000+ patients tested with Syn-One – and counting.

The Syn-One Test® from CND Life Sciences

The first commercially available skin-based test to help clinicians diagnose Parkinson’s disease and related disorders.

seal icon

CLIA-Certified and CAP-Accredited Pathology Lab

test tube icon

Dedication to Science, Research, Quality, and Reliability

DNA icon

Patient-Focused Mission

microscope icon

High Accuracy: >95% Sensitivity and Specificity

Clarity and Confidence of Syn-One

Having objective, visual proof of a disease process can be invaluable for physicians and patients. That’s why CND Life Sciences developed the Syn-One Test as a way to actually see the presence of abnormal alpha-synuclein in the skin–an important marker for Parkinson’s disease and other disorders known as synucleinopathies.  

Learn More

Our Commitment to Patients

We may not have coined the phrase “knowledge is power,” but it perfectly reflects our mission. Every day, patients and caregivers rely on physicians to make critical clinical decisions. That’s why we are dedicated to providing reliable diagnostic technologies and actionable insights that help optimize care.

Learn more about what drives us.

Learn More

CND Insights

Read our perspectives on the industry, the field of neurodiagnostics, patient care, and other topics.

Insights
April 8, 2026

What Is Small-Fiber Dx®?

Even when nerve conduction studies are normal, patients may still have isolated small fiber neuropathy.
Insights
March 12, 2026

CND Life Sciences Granted CLEP Laboratory Permit by New York State

CND Life Sciences (CND) announces that it has been granted a laboratory permit from the…
Insights
February 18, 2026

Information at Our Fingertips: How Wearable Technology Can Support Sleep-Related Diagnostics and Quality of Life in Synucleinopathies

Reaching a diagnosis of Parkinson's disease or related disorders provides an opportunity for clinician and…
VIEW ALL INSIGHTS

News

Check out press releases, news alerts and coverage of CND happenings.

CND In the News
June 22, 2026

Alpha-Synuclein Skin Biopsy Testing Linked to Lower Neurology Care Costs

Practical Neurology highlighted research presented at the 7th World Parkinson Congress evaluating neurologic care costs…
On Our Radar
June 15, 2026

Phosphorylated Alpha-Synuclein Skin Biopsy Alters Diagnosis in Two Out of Three Patients

A recent analysis published in Parkinsonism and Related Disorders examined how phosphorylated alpha-synuclein (P-SYN) skin…
CND In the News
June 4, 2026

REM-Sleep Behavior Disorder: An Early Window Into Synucleinopathies

A recent news article from Sleep Review highlights the growing recognition of REM Sleep Behavior…
VIEW ALL NEWS
CND CASE STUDIES

For Clinicians: Request a Skin Biopsy Test Kit

Our suite of neurodiagnostic tests provides clinicians with objective pathological insights on diseases that are often difficult to diagnose. Using our Skin Biopsy Test Kit, collect three small skin biopsies from your patient, send them to our CLIA-certified and CAP-accredited lab, and CND will provide important pathological insights to support a diagnosis.

Order a Kit